IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS

这项为期三年的第三阶段研究的目的是调查 伊班磷酸钠长期治疗慢性粒细胞白血病的疗效观察 绝经后骨质疏松症的疗效和安全性评价 间歇性静脉注射治疗新椎体的发生率 骨折作为主要终点。 具体目标是： 确定伊班磷酸钠是否能预防女性骨折和骨丢失 确诊为绝经后骨质疏松症。 以确定与静脉注射相关的副作用的类型。 伊班磷酸钠的管理。 测定治疗后血中伊班磷酸钠的含量 并估计药物在血液中停留的时间。

The purpose of this three year phase III study is to investigate the therapeutic effect of ibandronate in the long-term treatment of postmenopausal osteoporosis by evaluating the efficacy and safety of intermittent intravenous treatment using the incidence of new vertebral fractures as the primary endpoint. The specific objectives are: To determine whether Ibandronate prevents fractures and bone loss in women with established postmenopausal osteoporosis. To determine the type of side effects associated with the i.v. administration of Ibandronate. To determine the amount of Ibandronate in the blood following treatment and to estimate how long the drug stays in the blood.